Celcuity (CELC) Aandeel Koers
Celcuity Koers
Analisten hanteren een mediaan koersdoel van 155,00 USD — dat impliceert 122,3% boven de huidige koers. Van de 19 analisten geven 18 het aandeel een koopadvies — per saldo een Kopen-consensus.
Celcuity aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Celcuity bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Celcuity
Celcuity Inc, a targeted diagnostics company, operates on a unique business model focusing on developing and commercializing novel companion diagnostic tests. By analyzing a patient's living cancer cells used in diagnostic testing, Celcuity gathers crucial data to identify abnormal signaling pathways that can guide physicians in selecting the most effective treatment. Leveraging its proprietary CELsignia platform, Celcuity aims to improve patient outcomes by enabling the identification of patients who are likely to respond favorably to specific targeted therapies. Through its innovative approach, Celcuity strives to revolutionize personalized medicine in the field of cancer diagnostics.
Celcuity Inc is primarily active in the biotechnology industry.
The main competitors of Celcuity Inc in the market are large pharmaceutical companies such as Pfizer, Novartis, and Roche.
Celcuity Inc is a biotechnology company based in Minneapolis, Minnesota. Founded in 2012, Celcuity focuses on developing innovative therapeutic solutions for the treatment of cancer. The company specializes in discovering cancer subtypes by analyzing a patient's cells to identify abnormal signaling activity. By providing this personalized information, Celcuity aims to help healthcare professionals make more informed treatment decisions. With its cutting-edge platform and collaborations with renowned institutions, Celcuity Inc is committed to advancing precision medicine and improving patient outcomes in the field of oncology.
Celcuity Inc has achieved several significant milestones in its journey. The company has made remarkable progress in the field of precision medicine and oncology diagnostics. One of the notable achievements includes its successful initial public offering (IPO), which helped to raise funds for further research and development efforts. Moreover, Celcuity has successfully established collaborations with renowned academic institutions and pharmaceutical companies, allowing for the expansion of its product pipeline and access to a broader patient population. The continued advancements in their proprietary CELsignia platform have also provided valuable insights into the molecular signatures of various cancers, enhancing physicians' ability to personalize treatment strategies.
Celcuity Inc is primarily present in the United States.
Celcuity Inc represents the values of innovation, precision, and patient-centered care. As a biotechnology company, Celcuity is dedicated to developing and commercializing novel diagnostic tests to identify and treat cancer patients who can benefit from targeted therapies. Their corporate philosophy emphasizes the importance of using cutting-edge technology to improve patient outcomes and provide physicians with precise and actionable information. By harnessing the power of CELsignaling™, Celcuity strives to revolutionize therapeutic decision-making in oncology. Through their relentless pursuit of scientific advancements, Celcuity Inc aims to make a significant and positive impact in the field of precision medicine.
Analisten hanteren momenteel een gemiddeld koersdoel van 154,33 USD voor het aandeel Celcuity (mediaan: 155,00 USD), oftewel +121,4 % ten opzichte van de laatste koers. De consensus is gebaseerd op 19 analistenratings.
19 analisten beoordelen het aandeel Celcuity momenteel: 18 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat Celcuity een omzet van 23,34 Miljoen USD en winst per aandeel van -3,86 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Celcuity op 62,04 EUR (69,72 USD).
Het aandeel Celcuity (CELC) is genoteerd aan 1 beurzen, waaronder: NASDAQ (CELC).
Celcuity Inc is a US biotechnology company specializing in the development of precision medicine solutions for the treatment of cancer. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota. Celcuity operates in two business areas: drug development and diagnostic test development. Celcuity's drug development is based on the discovery of new mechanistic target molecules that play a role in cancer formation. The company is working intensively to develop drugs that specifically target these targets to achieve better efficacy and tolerability in cancer therapy. The second business area is the development of diagnostic tests. Celcuity has developed a novel diagnostic procedure that identifies the molecular signature of cancer cells, enabling rapid and targeted diagnosis. These tests can help identify patient groups most likely to benefit from specific cancer treatments, leading to better and personalized therapies. Celcuity already offers various diagnostic tests, including the CELx HER2 Signaling Function Test, which measures the HER2 signaling pathway in tumor cells, allowing prediction of the efficacy of various HER2-targeted therapies. Celcuity's business model is based on the development of innovative solutions based on precision medicine approaches. The company collaborates with renowned research institutions and pharmaceutical companies. Celcuity is a publicly traded company financed through the sale of shares. The company has invested significantly in research and development in recent years and has acquired several patents to protect its technology. Celcuity aims to improve the lives of cancer patients through the development of better treatment options and a personalized approach. Collaboration with the medical community and the development of innovative diagnostic tests are key priorities. Overall, Celcuity is a promising biotechnology company leading in the field of precision medicine for cancer therapy. The company has made significant progress in recent years and is committed to revolutionizing cancer therapy through the provision of personalized treatments.
De verwachte omzet van Celcuity bedraagt 23,34 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Celcuity bedraagt -202,73 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Celcuity bedraagt momenteel -18,07. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Celcuity-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Celcuity bedraagt momenteel 156,94. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Celcuity-aandeel.
De Eulerpool Kwaliteitsscore voor Celcuity is 4/10.
De ISIN van Celcuity is US15102K1007. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Celcuity is A2JAAX. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Celcuity is CELC. Onder dit beurstickersymbool wordt het Celcuity-aandeel op de beurs verhandeld.
Celcuity aandeel
Celcuity Peer Group
Celcuity Ticker
Celcuity FIGI
Alle fundamentals en diepgaande analyse van Celcuity
Onze aandelenanalyse van het Celcuity-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Celcuity. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: